[go: up one dir, main page]

PE20030065A1 - Metodos para administrar anticuerpos anti-tnfalfa - Google Patents

Metodos para administrar anticuerpos anti-tnfalfa

Info

Publication number
PE20030065A1
PE20030065A1 PE2002000478A PE2002000478A PE20030065A1 PE 20030065 A1 PE20030065 A1 PE 20030065A1 PE 2002000478 A PE2002000478 A PE 2002000478A PE 2002000478 A PE2002000478 A PE 2002000478A PE 20030065 A1 PE20030065 A1 PE 20030065A1
Authority
PE
Peru
Prior art keywords
antigen
tnfo
refers
antibody
recombining
Prior art date
Application number
PE2002000478A
Other languages
English (en)
Inventor
Joachim Kempeni
Roberta Weiss
Steven Fischkoff
Original Assignee
Abbott Lab Bermuda Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23144283&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20030065(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab Bermuda Ltd filed Critical Abbott Lab Bermuda Ltd
Publication of PE20030065A1 publication Critical patent/PE20030065A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)

Abstract

SE REFIERE AL USO DE UNA COMPOSICION QUE CONTIENE UN ANTICUERPO ANTI-TNFO O UNA PORCION DE UNION A ANTIGENO DEL MISMO QUE SE DISOCIA CON UNA CONSTANTE DE VELOCIDAD Koff DE 5 x 10 -4 s-1. LA PORCION DE UNION A ANTIGENO DEL MISMO NEUTRALIZA LA CITOXICIDAD CAUSADA POR EL TNFO HUMANO EN UN ENSAYO COMUN IN VITRO L929 CON UNA IC50 DE 1x10 -9 M O MENOS Y ES UN ANTICUERPO RECOMBINANTE O UNA PORCION RECOMBINANTE DE UNION A ANTIGENO DEL MISMO. SE REFIERE TAMBIEN A COMPOSICIONES FARMACEUTICAS QUE SE USAN EN UN REGIMEN DE DOSIFICACION CADA DOS SEMANAS PARA INHIBIR LA ACTIVIDAD DE TNFO EN UN SUJETO DONDE DICHO ANTICUERPO TIENE LAS SIGUIENTES CARACTERISTICAS: a) SE DISOCIA DEL TNFO HUMANO CON UNA CONSTANTE DE VELOCIDAD Koff DE 1 x 10 -3 s-1; b) TIENE UN DOMINIO DE CADENA LIVIANA CDR3 QUE COMPRENDE LA SECUENCIA SEQ ID N° 3 Y C) TIENE UN DOMINIO DE CADENA PESADA CDR3 QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS DE SEQ ID N° 4
PE2002000478A 2001-06-08 2002-06-07 Metodos para administrar anticuerpos anti-tnfalfa PE20030065A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29696101P 2001-06-08 2001-06-08

Publications (1)

Publication Number Publication Date
PE20030065A1 true PE20030065A1 (es) 2003-02-12

Family

ID=23144283

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2002000478A PE20030065A1 (es) 2001-06-08 2002-06-07 Metodos para administrar anticuerpos anti-tnfalfa
PE2016001292A PE20160999A1 (es) 2001-06-08 2002-06-07 Metodos para administrar anticuerpos anti-tnf-alfa

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2016001292A PE20160999A1 (es) 2001-06-08 2002-06-07 Metodos para administrar anticuerpos anti-tnf-alfa

Country Status (32)

Country Link
US (16) US8889135B2 (es)
EP (6) EP2364731A3 (es)
JP (7) JP2005517629A (es)
KR (8) KR20100075698A (es)
CN (5) CN103110944A (es)
AR (3) AR034429A1 (es)
AU (1) AU2002314922C1 (es)
BG (2) BG66459B1 (es)
BR (1) BR0206289A (es)
CA (3) CA2385745C (es)
CL (1) CL2012000856A1 (es)
CY (1) CY1120540T1 (es)
CZ (1) CZ309160B6 (es)
DK (2) DK1406656T3 (es)
EC (1) ECSP034867A (es)
ES (2) ES2612436T3 (es)
HU (1) HU230947B1 (es)
IL (4) IL158831A0 (es)
LT (1) LT2940044T (es)
MX (2) MXPA03011316A (es)
NO (2) NO334490B1 (es)
NZ (6) NZ529574A (es)
PE (2) PE20030065A1 (es)
PH (3) PH12013500297A1 (es)
PL (4) PL215861B1 (es)
PT (2) PT2940044T (es)
SA (1) SA02230384B1 (es)
SI (2) SI1406656T1 (es)
SK (1) SK288509B6 (es)
TW (1) TWI473622B (es)
WO (1) WO2002100330A2 (es)
ZA (1) ZA200308861B (es)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
CZ292465B6 (cs) 1996-02-09 2003-09-17 Abbott Laboratories (Bermuda) Ltd. Lidské protilátky k lidskému TNFalfa
CA2385745C (en) * 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20030206898A1 (en) * 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
DK1944322T3 (da) * 2002-07-19 2015-06-22 Abbvie Biotechnology Ltd Behandling af TNFalfa-relaterede sygdomme
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
WO2004087730A2 (en) * 2003-03-27 2004-10-14 The Johns Hopkins University Method for producing diverse libraries of encoded polymers
US7344716B2 (en) * 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US8273347B2 (en) * 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US7892563B2 (en) * 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
US8361467B2 (en) * 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
TWI439284B (zh) * 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd 用於治療ＴＮＦα相關失調症之多重可變劑量療法
AU2011218744B2 (en) * 2004-04-09 2012-09-20 Abbvie Biotechnology Ltd Multiple-variable dose regimen for treating TNFalpha-related disorders
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
US20060024308A1 (en) * 2004-07-06 2006-02-02 Roberto Crea High affinity anti-TNF-alpha antibodies and method
US20060083741A1 (en) * 2004-10-08 2006-04-20 Hoffman Rebecca S Treatment of respiratory syncytial virus (RSV) infection
US20060253100A1 (en) 2004-10-22 2006-11-09 Medtronic, Inc. Systems and Methods to Treat Pain Locally
ES2417065T3 (es) 2005-04-26 2013-08-05 Trion Pharma Gmbh Combinación de anticuerpos con glucocorticoides para el tratamiento del cáncer
JP5757495B2 (ja) 2005-05-16 2015-07-29 アッヴィ バイオテクノロジー リミテッド びらん性多発性関節炎の治療のためのｔｎｆ阻害剤の使用
AU2012254978C1 (en) * 2005-05-16 2017-06-01 Abbvie Biotechnology Ltd Use of TNF inhibitor for treatment of erosive polyarthritis
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
EP2357479A1 (en) 2005-11-01 2011-08-17 Abbott Biotechnology Ltd Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
WO2007110219A1 (en) * 2006-03-27 2007-10-04 Ablynx N.V. Medical delivery device for therapeutic proteins based on single domain antibodies
ES2550004T3 (es) 2006-04-04 2015-11-03 Singulex, Inc. Sistema de alta sensibilidad y métodos de análisis de la troponina
RU2466740C2 (ru) 2006-04-05 2012-11-20 Эбботт Байотекнолоджи Лтд. Очистка антитела
EP2012586A4 (en) 2006-04-10 2010-08-18 Abbott Biotech Ltd USES AND COMPOSITIONS FOR THE TREATMENT OF ANKYLOSANTE SPONDYLARTHRITIS
WO2007120651A2 (en) * 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of juvenile rheumatoid arthritis
US9399061B2 (en) * 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US9605064B2 (en) * 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
CA2564435A1 (en) 2006-04-10 2007-10-10 Abbott Biotechnology Ltd. Methods for monitoring and treating intestinal disorders
EP2666478A3 (en) 2006-04-10 2014-10-22 AbbVie Biotechnology Ltd Uses and compositions for treatment of psoriasis
WO2008063213A2 (en) * 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
US20090317399A1 (en) * 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
AU2006342608A1 (en) * 2006-04-25 2007-11-01 Intercell Ag HCV vaccinations
US20080311043A1 (en) * 2006-06-08 2008-12-18 Hoffman Rebecca S Uses and compositions for treatment of psoriatic arthritis
US20100021451A1 (en) 2006-06-08 2010-01-28 Wong Robert L Uses and compositions for treatment of ankylosing spondylitis
CN107243099A (zh) 2006-06-30 2017-10-13 艾伯维生物技术有限公司 自动注射装置
NZ576133A (en) 2006-10-27 2012-10-26 Abbott Biotech Ltd Crystalline anti-htnfalpha antibodies
EP2165194A4 (en) * 2007-05-31 2010-09-08 Abbott Lab BIOMARKERS FOR PREDICTING RESPONSABILITY TO TNF ALPHA INHIBITORS IN AUTOIMMUNE DISEASES
EP2171451A4 (en) 2007-06-11 2011-12-07 Abbott Biotech Ltd METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
EP2173380A4 (en) * 2007-07-13 2011-08-31 Abbott Biotech Ltd METHOD AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa HEMMER
US8753839B2 (en) 2007-08-08 2014-06-17 Abbvie Inc. Compositions and methods for crystallizing antibodies
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
KR20210049186A (ko) 2007-11-30 2021-05-04 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
US8986696B2 (en) 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
PL2808343T3 (pl) 2007-12-26 2019-11-29 Xencor Inc Warianty Fc ze zmienionym wiązaniem do FcRn
MX2010007393A (es) * 2008-01-03 2010-11-09 Abbott Biotech Ltd Anticipacion de eficacia a largo plazo de un compuesto en el tratamiento de psoriasis.
SG2013054218A (en) 2008-01-15 2014-10-30 Abbott Gmbh & Co Kg Powdered protein compositions and methods of making same
MX2010010503A (es) * 2008-03-24 2010-11-09 Abbott Biotech Ltd Metodos y composiciones para tratar perdida osea.
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US20100239632A1 (en) 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
TWI559930B (en) 2009-04-16 2016-12-01 Abbvie Biotherapeutics Inc Anti-tnf-α antibodies and their uses
NZ595885A (en) 2009-04-29 2014-05-30 Abbvie Biotechnology Ltd Automatic injection device
JP5940981B2 (ja) 2009-12-15 2016-06-29 アッヴィ バイオテクノロジー リミテッド 自動注射装置のための改善された作動ボタン
US20110150891A1 (en) * 2009-12-16 2011-06-23 Philip Bosch Methods of Treating Interstitial Cystitis
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
CA2789168A1 (en) 2010-02-02 2011-08-11 Abbott Biotechnology Ltd. Methods and compositions for predicting responsiveness to treatment with tnf-.alpha. inhibitor
NZ702172A (en) 2010-04-21 2016-03-31 Abbvie Biotechnology Ltd Wearable automatic injection device for controlled delivery of therapeutic agents
WO2011146727A1 (en) 2010-05-19 2011-11-24 Philip Bosch Methods of treating interstitial cystitis
JP5944382B2 (ja) 2010-06-03 2016-07-05 アッヴィ バイオテクノロジー リミテッド 汗腺膿瘍（ｈｓ）の治療のための使用および組成物
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
RU2015154965A (ru) 2010-11-11 2019-01-16 Эббви Байотекнолоджи Лтд. Улучшенные высококонцентрированные жидкие препараты антител против tnf альфа
EP2749305B1 (en) 2011-01-24 2017-11-01 AbbVie Biotechnology Ltd Automatic injection devices having overmolded gripping surfaces
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP4438625A3 (en) * 2011-05-02 2024-12-11 Millennium Pharmaceuticals, Inc. Formulation for anti-alpha4beta7 antibody
KR102103036B1 (ko) 2011-06-13 2020-04-22 압제노믹스 코오페라티에프 유.에이. 항-ｐｓｇｌ-１ 항체 및 그의 용도
CA2857597A1 (en) 2011-11-30 2013-06-06 AbbVie Deutschland GmbH & Co. KG Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9206390B2 (en) 2012-09-02 2015-12-08 Abbvie, Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
PE20191815A1 (es) 2012-09-07 2019-12-27 Coherus Biosciences Inc Formulaciones acuosas estables de adalimumab
CA2905010A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
AU2014337263B2 (en) 2013-10-16 2019-12-12 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US9763992B2 (en) 2014-02-13 2017-09-19 Father Flanagan's Boys' Home Treatment of noise induced hearing loss
GB201407852D0 (en) * 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
US11548940B2 (en) 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10689460B2 (en) 2014-05-15 2020-06-23 Incube Labs, Llc PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10039810B2 (en) * 2014-05-15 2018-08-07 Incube Labs, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising anti-interleukin antibodies
EP3145951A1 (en) 2014-06-24 2017-03-29 InSight Biopharmaceuticals Ltd. Methods of purifying antibodies
IL250302B (en) 2014-07-31 2022-07-01 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
CN104382977A (zh) * 2014-11-17 2015-03-04 昆明朗盛生物科技有限公司 一种女性专用的玛咖组合物
EP3237000A1 (en) 2014-12-23 2017-11-01 Pfizer Inc Stable aqueous antibody formulation for anti tnf alpha antibodies
EP3247718B1 (en) 2015-01-21 2021-09-01 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
EP3078675A1 (en) 2015-04-10 2016-10-12 Ares Trading S.A. Induction dosing regimen for the treatment of tnf alpha mediated disorders
CN107847446A (zh) 2015-05-01 2018-03-27 因库博实验室有限责任公司 药物组合物和用于制备包含多肽和/或蛋白质的固体块的方法
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
EP3374399A1 (en) 2015-11-11 2018-09-19 Opi Vi- IP Holdco LLC Composition and methods for anti-tnfr2 antibodies
JP7084308B2 (ja) 2016-02-03 2022-06-14 アウトルック セラピューティクス，インコーポレイティド 抗体安定性を増大させるための緩衝液製剤
SG10202012182YA (en) * 2016-03-07 2021-01-28 Sanofi Biotechnology Compositions and methods for treating rheumatoid arthritis
WO2017184880A1 (en) 2016-04-20 2017-10-26 Coherus Biosciences, Inc. A method of filling a container with no headspace
CA3025377A1 (en) 2016-06-02 2017-12-07 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
KR20190024572A (ko) * 2017-08-30 2019-03-08 (주)셀트리온 TNFα 관련 질환을 치료하기 위한 피하 투여 요법
EP3456739A1 (en) * 2017-09-19 2019-03-20 Tillotts Pharma Ag Use of anti-tnfalpha antibodies for treating wounds
US10772970B2 (en) 2017-12-01 2020-09-15 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
MX2021002422A (es) 2018-08-29 2021-07-15 Regeneron Pharma Métodos y composiciones para el tratamiento de sujetos que padecen artritis reumatoide.
BR112021014377A2 (pt) 2019-01-31 2021-12-28 Regeneron Pharma Composições e métodos para o tratamento de artrite idiopática juvenil
AR118191A1 (es) * 2019-02-28 2021-09-22 Celltrion Inc MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa
CA3130348A1 (en) * 2019-03-14 2020-09-17 Motti HAKIM A method for immunosuppression
MA55760A (fr) 2019-04-24 2022-03-02 Regeneron Pharma Procédés de diagnostic et de traitement de la polyarthrite rhumatoïde
WO2020247461A1 (en) 2019-06-04 2020-12-10 Sanofi Biotechnology Compositions and methods for treating pain in subj ects with rheumatoid arthritis
TW202128748A (zh) * 2020-01-24 2021-08-01 日商西斯美股份有限公司 提升抗體對抗原之親和性的方法及其用途
TW202509220A (zh) * 2023-06-26 2025-03-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 經工程化之瘧原蟲及相關方法
KR20250031013A (ko) * 2023-08-23 2025-03-06 (주)셀트리온 TNFα 관련 질환을 치료하는 방법

Family Cites Families (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
WO1983000930A1 (en) 1981-09-08 1983-03-17 Univ Rockefeller Lipoprotein lipase suppression by endotoxin-induce mediator (shock assay)
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
IL73883A (en) 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
DE3650150T2 (de) 1985-08-16 1995-04-27 The Rockefeller University, New York, N.Y. Modulator der anabolischen Aktivität und seine Verwendungen.
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
US5246714A (en) 1985-10-11 1993-09-21 Aktiebolaget Hassle Drug preparation
GB8528234D0 (en) 1985-11-15 1985-12-18 Wyeth John & Brother Ltd Heterocyclic compounds
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
EP0230574A3 (en) 1986-01-31 1989-03-22 Yale University Pharmaceutical compositions against infections caused by lav/htlv iii virus and the use thereof
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
AU626572B2 (en) 1988-07-18 1992-08-06 Chiron Corporation Monoclonal antibodies reactive with cachectin
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68914244T2 (de) 1988-10-24 1994-10-27 Otsuka Pharma Co Ltd Monoklonaler Antikörper.
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
EP0374510B1 (en) 1988-12-19 1997-01-15 American Cyanamid Company Products for the treatment of endotoxic shock in a mammal
JP3443119B2 (ja) 1989-08-07 2003-09-02 ペプテック リミテッド 腫瘍壊死因子結合リガンド
FR2651130B1 (fr) * 1989-08-23 1991-12-13 Roussel Uclaf Sequence d'oligonucleotides anti-sens, anti-arn message du tnf alpha, procede de preparation, application a titre de medicaments et compositions pharmaceutiques.
GB8921123D0 (en) 1989-09-19 1989-11-08 Millar Ann B Treatment of ards
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5945098A (en) * 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
DE4037604A1 (de) 1990-04-25 1991-10-31 Bayer Ag Verwendung von anti-tnf-antikoerpern als arzneimittel bei der behandlung von ischaemien und deren folgen
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2090401A1 (en) 1990-08-27 1992-02-28 Deborah A. Rathjen Method of treating viral infection
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
GB2279077B (en) 1990-12-21 1995-06-14 Celltech Ltd Therapeutic compositions comprising recombinant antibodies specific for the TNFalpha
US5994510A (en) * 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
GB9028123D0 (en) 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
AU1545692A (en) 1991-03-01 1992-10-06 Protein Engineering Corporation Process for the development of binding mini-proteins
WO1992016221A1 (en) 1991-03-15 1992-10-01 Synergen, Inc. Pegylation of polypeptides
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US20060246073A1 (en) * 1991-03-18 2006-11-02 Knight David M Anti-TNF antibodies and peptides of human tumor necrosis factor
US20070298040A1 (en) * 1991-03-18 2007-12-27 Centocor, Inc. Methods of treating seronegative arthropathy with anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US20040120952A1 (en) * 2000-08-07 2004-06-24 Centocor, Inc Anti-TNF antibodies and peptides of human tumor necrosis factor
EP0610201B2 (en) 1991-03-18 2007-09-26 New York University Monoclonal and chimeric antibodies specific for human tumor necrosis factor
EP0604418B1 (en) 1991-03-29 1998-09-23 Immunex Corporation Isolated viral protein cytokine antagonists
DE69233367T2 (de) 1991-04-10 2005-05-25 The Scripps Research Institute, La Jolla Bibliotheken heterodimerer rezeptoren mittels phagemiden
EP0940468A1 (en) * 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DK0605522T3 (da) 1991-09-23 2000-01-17 Medical Res Council Fremgangsmåde til fremstilling af humaniserede antistoffer
WO1993011793A1 (en) 1991-12-17 1993-06-24 Schering Corporation Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock
US5195967A (en) * 1992-02-18 1993-03-23 Nakao Naomi L Anticlotting device and method for use with IV catheters
DE69331265T2 (de) 1992-04-02 2002-08-08 Smithkline Beecham Corp., Philadelphia Verbindungen zur behandlung von entzündlichen erkrankungen und zur hemmung der produktion von tumornekrosefaktor
DE69321909T2 (de) 1992-08-28 1999-04-01 Bayer Corp., Pittsburgh, Pa. Verwendung von monoklonalen Anti-TNF-Antikörpern für die Behandlung von bakteriellen Meningitiden
NZ256293A (en) 1992-09-15 1997-06-24 Immunex Corp Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
AU682156B2 (en) 1992-10-15 1997-09-25 Dana-Farber Cancer Institute, Inc. Treatment of insulin resistance in obesity linked type II diabetes using antagonists to TNF-alpha function
DE69427928T3 (de) * 1993-03-05 2012-05-10 Bayer Healthcare Llc Humane monoklonale anti-TNF alpha Antikörper
DE4307508A1 (de) 1993-03-10 1994-09-15 Knoll Ag Verwendung von anti-TNF-Antikörpern als Arzneimittel bei der Behandlung von Herzinsuffizienz (Herzmuskelschwäche)
CA2163032C (en) 1993-06-03 2001-02-06 John Landon Antibody fragments in therapy
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US5500227A (en) 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
NZ278607A (en) 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
EP0748338A4 (en) 1994-03-04 2001-03-28 Merck & Co Inc IN VITRO MATURATION OF ANTIBODIES BY MEANS OF ALANINE 'SCANNING' MUTAGENESIS
ZA955642B (en) * 1994-07-07 1997-05-06 Ortho Pharma Corp Lyophilized imaging agent formulation
EP1516628B1 (en) 1995-07-27 2013-08-21 Genentech, Inc. Stable isotonic lyophilized protein formulation
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
CZ292465B6 (cs) * 1996-02-09 2003-09-17 Abbott Laboratories (Bermuda) Ltd. Lidské protilátky k lidskému TNFalfa
GB9610992D0 (en) * 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
WO1998004281A1 (en) 1996-07-26 1998-02-05 Smithkline Beecham Corpration Improved method of treating immune cell mediated systemic diseases
WO1998056418A1 (en) 1997-06-13 1998-12-17 Genentech, Inc. Stabilized antibody formulation
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US5971953A (en) * 1998-01-09 1999-10-26 Bachynsky; Nicholas Dual chamber syringe apparatus
SK19052000A3 (sk) 1998-06-15 2001-06-11 Sepracor, Inc. Použitie (+)norcisapridu alebo jeho farmaceuticky prijateľnej soli, v podstate bez jeho (-)stereoizoméru na liečenie apnoe, bulímie a iných porúch
JP3889197B2 (ja) * 1999-02-22 2007-03-07 中外製薬株式会社 プランジャロッド付きシリンジ製剤の製造方法及びその組付装置
US6537549B2 (en) * 1999-02-24 2003-03-25 Edward L. Tobinick Cytokine antagonists for the treatment of localized disorders
US6419944B2 (en) * 1999-02-24 2002-07-16 Edward L. Tobinick Cytokine antagonists for the treatment of localized disorders
US6015557A (en) * 1999-02-24 2000-01-18 Tobinick; Edward L. Tumor necrosis factor antagonists for the treatment of neurological disorders
US6423321B2 (en) * 1999-02-24 2002-07-23 Edward L. Tobinick Cytokine antagonists for the treatment of sensorineural hearing loss
JP2002538170A (ja) 1999-03-02 2002-11-12 セントコール， インコーポレイテッド 喘息の治療における抗−ＴＮＦα抗体
PT1041072E (pt) * 1999-03-31 2003-11-28 Pfizer Prod Inc Acidos dioxociclopentil hidroxamicos
SE9901366D0 (sv) * 1999-04-16 1999-04-16 Pharmacia & Upjohn Ab Injector device and method for its operation
EP1174148A4 (en) 1999-04-28 2005-05-04 Yamanouchi Pharma Co Ltd PARENTAL MEDICAL COMPOSITIONS CONTAINING FRAGMENTS OF HUMANIZED MONOCLONAL ANTIBODIES AND METHOD FOR STABILIZING THE SAME
US20020017789A1 (en) 1999-06-16 2002-02-14 Holmes William W. Gland pipe fitting
JP2003503360A (ja) 1999-06-24 2003-01-28 ファルマシア コーポレイション 炎症性疾患の処置のための併用療法
TWI245645B (en) 1999-09-08 2005-12-21 Chugai Pharmaceutical Co Ltd Protein solution formulations and stabilization methods thereof
AU3082401A (en) 1999-11-24 2001-06-04 Centocor Inc. Therapy of psoriasis
EP1254666A4 (en) 1999-12-28 2004-12-22 Chugai Pharmaceutical Co Ltd STABLE ANTIBODY COMPOSITIONS AND INJECTION FORMULATIONS
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
US20050249735A1 (en) * 2000-08-07 2005-11-10 Centocor, Inc. Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
US20060018907A1 (en) * 2000-08-07 2006-01-26 Centocor, Inc. Anti-TNF antibodies and peptides of human tumor necrosis factor
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
BR0206160A (pt) 2001-05-25 2004-10-26 Abbott Gmbh & Co Kg Uso de anticorpos anti-tnf como medicamentos no tratamento de distúrbios sépticos de pacientes anêmicos
CA2385745C (en) * 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
PT1425389E (pt) * 2001-08-23 2012-02-07 Genmab As Anticorpos humanos específicos para interleucina 15 (il-15)
US20030161828A1 (en) * 2002-02-19 2003-08-28 Abbott Gmbh & Co. Kg Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure
WO2003080672A1 (en) 2002-03-22 2003-10-02 Aprogen, Inc. Humanized antibody and process for preparing same
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
DK1944322T3 (da) * 2002-07-19 2015-06-22 Abbvie Biotechnology Ltd Behandling af TNFalfa-relaterede sygdomme
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
US7226426B2 (en) 2002-07-25 2007-06-05 Thomson Paul E Apparatus and method for the detection and quantification of joint and tissue inflammation
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
TWI439284B (zh) * 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd 用於治療ＴＮＦα相關失調症之多重可變劑量療法
US20060083741A1 (en) * 2004-10-08 2006-04-20 Hoffman Rebecca S Treatment of respiratory syncytial virus (RSV) infection
JP5757495B2 (ja) * 2005-05-16 2015-07-29 アッヴィ バイオテクノロジー リミテッド びらん性多発性関節炎の治療のためのｔｎｆ阻害剤の使用
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
EP2357479A1 (en) * 2005-11-01 2011-08-17 Abbott Biotechnology Ltd Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
RU2466740C2 (ru) * 2006-04-05 2012-11-20 Эбботт Байотекнолоджи Лтд. Очистка антитела
US9605064B2 (en) * 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
CN107243099A (zh) * 2006-06-30 2017-10-13 艾伯维生物技术有限公司 自动注射装置
NZ576133A (en) * 2006-10-27 2012-10-26 Abbott Biotech Ltd Crystalline anti-htnfalpha antibodies
US8753839B2 (en) * 2007-08-08 2014-06-17 Abbvie Inc. Compositions and methods for crystallizing antibodies
WO2014152463A1 (en) 2013-03-15 2014-09-25 Cyberheart, Inc. Apparatus and method for real-time tracking of tissue structures
NZ595885A (en) * 2009-04-29 2014-05-30 Abbvie Biotechnology Ltd Automatic injection device
KR20120038406A (ko) * 2009-05-04 2012-04-23 애보트 바이오테크놀로지 리미티드 인간 항?ＴＮＦ?α 항체의 안정한 고 단백질 농도 제형
CN102167741B (zh) 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗TNF-α单克隆抗体、其制备方法及用途
JP5944382B2 (ja) * 2010-06-03 2016-07-05 アッヴィ バイオテクノロジー リミテッド 汗腺膿瘍（ｈｓ）の治療のための使用および組成物
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
CN104981208B (zh) 2013-03-22 2018-04-13 东芝医疗系统株式会社 超声波诊断装置及其控制程序
KR102197477B1 (ko) 2014-07-04 2020-12-31 주식회사 유풍 모자

Also Published As

Publication number Publication date
PL217702B1 (pl) 2014-08-29
US20150165023A1 (en) 2015-06-18
BG66936B1 (bg) 2019-08-15
AR034429A1 (es) 2004-02-25
HU230947B1 (hu) 2019-05-28
US9546212B2 (en) 2017-01-17
US9073987B2 (en) 2015-07-07
AR077572A2 (es) 2011-09-07
NZ529574A (en) 2006-05-26
MX341001B (es) 2016-08-03
BG108514A (en) 2005-04-30
EP1406656B1 (en) 2013-01-09
HUP0600688A2 (en) 2006-11-28
BR0206289A (pt) 2004-11-30
TWI473622B (zh) 2015-02-21
AU2002314922C1 (en) 2017-11-09
CN1638796A (zh) 2005-07-13
KR20040030661A (ko) 2004-04-09
DK2940044T3 (en) 2017-02-20
JP6302529B2 (ja) 2018-03-28
US20150079101A1 (en) 2015-03-19
US8911737B2 (en) 2014-12-16
PE20160999A1 (es) 2016-10-08
EP1406656A4 (en) 2006-05-24
PH12013500866B1 (en) 2016-02-22
SK16462003A3 (sk) 2004-08-03
US20140271637A1 (en) 2014-09-18
HUP0600688A3 (en) 2012-09-28
KR101282807B1 (ko) 2013-07-05
NZ586063A (en) 2012-02-24
PH12013500866A1 (en) 2016-02-22
KR20100075698A (ko) 2010-07-02
JP6074462B2 (ja) 2017-02-01
WO2002100330A2 (en) 2002-12-19
NZ573478A (en) 2011-02-25
US8974790B2 (en) 2015-03-10
IL158831A (en) 2014-06-30
NO343721B1 (no) 2019-05-20
US20150023982A1 (en) 2015-01-22
PL217666B1 (pl) 2014-08-29
PT1406656E (pt) 2013-03-25
US20160280777A1 (en) 2016-09-29
KR101715028B1 (ko) 2017-03-10
AU2002314922B2 (en) 2008-05-15
WO2002100330A9 (en) 2007-06-21
KR20080089681A (ko) 2008-10-07
US8992926B2 (en) 2015-03-31
IL222495A (en) 2015-03-31
CY1120540T1 (el) 2019-07-10
IL158831A0 (en) 2004-05-12
BG111719A (bg) 2014-06-30
EP3190124A1 (en) 2017-07-12
TW201332570A (zh) 2013-08-16
JP2005517629A (ja) 2005-06-16
US20150071939A1 (en) 2015-03-12
CZ200420A3 (cs) 2005-01-12
JP2015166389A (ja) 2015-09-24
KR101497363B1 (ko) 2015-03-03
WO2002100330A3 (en) 2004-02-12
PH12013500865B1 (en) 2018-06-27
SA02230384B1 (ar) 2009-08-19
US20200181252A1 (en) 2020-06-11
SI2940044T1 (sl) 2017-03-31
EP2940044B8 (en) 2017-01-18
KR101142825B1 (ko) 2012-05-08
MXPA03011316A (es) 2004-12-06
ES2400458T3 (es) 2013-04-10
US20150175691A1 (en) 2015-06-25
ECSP034867A (es) 2004-01-28
PL399491A1 (pl) 2012-10-08
PL366694A1 (en) 2005-02-07
US9017680B2 (en) 2015-04-28
SI1406656T1 (sl) 2013-04-30
US20150071945A1 (en) 2015-03-12
PH12013500297A1 (en) 2015-09-07
NZ596878A (en) 2013-07-26
CN105412922A (zh) 2016-03-23
HK1065471A1 (en) 2005-02-25
KR20140012210A (ko) 2014-01-29
PT2940044T (pt) 2017-01-12
JP2015003922A (ja) 2015-01-08
EP2940044B1 (en) 2016-11-16
IL212419A (en) 2015-03-31
EP2324851A1 (en) 2011-05-25
JP2012184242A (ja) 2012-09-27
EP2364731A3 (en) 2011-11-02
EP2359855A9 (en) 2012-06-20
NO20035426D0 (no) 2003-12-05
KR20090035746A (ko) 2009-04-10
ZA200308861B (en) 2004-09-13
US20120177596A1 (en) 2012-07-12
AR090099A2 (es) 2014-10-22
EP2940044A1 (en) 2015-11-04
CA2868614A1 (en) 2002-12-08
JP2013100311A (ja) 2013-05-23
PL399548A1 (pl) 2012-11-05
CZ309160B6 (cs) 2022-03-30
CL2012000856A1 (es) 2012-09-14
NZ560792A (en) 2009-09-25
PL394085A1 (pl) 2011-07-04
PL215861B1 (pl) 2014-02-28
NZ545649A (en) 2009-04-30
DK1406656T3 (da) 2013-04-15
NO334490B1 (no) 2014-03-17
US20150017175A1 (en) 2015-01-15
LT2940044T (lt) 2017-01-10
US20140322232A1 (en) 2014-10-30
US20030235585A1 (en) 2003-12-25
PH12013500865A1 (en) 2016-02-01
JP2017031213A (ja) 2017-02-09
NO20120288L (no) 2004-02-03
US20150246968A1 (en) 2015-09-03
KR20110039505A (ko) 2011-04-18
EP1406656A2 (en) 2004-04-14
US8889135B2 (en) 2014-11-18
PL217217B1 (pl) 2014-06-30
US20130004507A1 (en) 2013-01-03
ES2612436T3 (es) 2017-05-16
EP2359855A2 (en) 2011-08-24
CA2385745A1 (en) 2002-12-08
BG66459B1 (bg) 2014-10-31
JP2009167193A (ja) 2009-07-30
EP2364731A9 (en) 2012-06-20
CA2385745C (en) 2015-02-17
CN103110944A (zh) 2013-05-22
SK288509B6 (sk) 2017-11-03
EP2364731A2 (en) 2011-09-14
EP2359855A3 (en) 2011-11-02
KR20160096222A (ko) 2016-08-12
NO20035426L (no) 2004-02-03
CN101574520A (zh) 2009-11-11
CA2817619A1 (en) 2002-12-08
KR20120139851A (ko) 2012-12-27
JP5832952B2 (ja) 2015-12-16
IL212419A0 (en) 2011-06-30
CN103495165A (zh) 2014-01-08
US20140186368A1 (en) 2014-07-03

Similar Documents

Publication Publication Date Title
PE20030065A1 (es) Metodos para administrar anticuerpos anti-tnfalfa
ES2657443T3 (es) Anticuerpos anti-GITR y usos de los mismos
AR104198A2 (es) Formulaciones de proteínas y anticuerpos de alta concentración
PE20050925A1 (es) Anticuerpo recombinante humanizado anti-interleuquina 10
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
PE20220708A1 (es) Anticuerpos anti-cd73
AR102732A1 (es) Moléculas de unión a antígeno biespecíficas activadoras de células t
AR095432A1 (es) Proteínas de unión a antígeno
PE20091205A1 (es) Anticuerpo anti-receptor de il-6
CO6220978A2 (es) Anticuerpos dirigidos a proteina-1 quimio-tactica de monocitos (mcp-1)y sus usos
CO6180445A2 (es) Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3
AR021296A1 (es) Un anticuerpo humanizado especifico para 4-1bb humano y composiciones farmaceuticas que lo comprenden
CO5470287A1 (es) Antagonistas recombinantes de il-18 utiles en el tratamiento de trastornos mediados por il-18
ES2180754T3 (es) Compuestos y metodos para la deteccion de infeccion por t. cruzi.
PE20240819A1 (es) Anticuerpos anti-hla-g y uso de estos
BRPI0314038B8 (pt) anticorpo humano isolado, molécula de ácido nucleico isolada, vetor, uso de um anticorpo, e, composição farmacêutica
ID30497A (id) Peptida hiv, antigen, komposisi vaksin, kit imunoasai dan metoda untuk mendeteksi antibodi yang diinduksi oleh hiv
PE20230389A1 (es) Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas
PE20140882A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
AR046379A1 (es) Una molecula de enlace de mcp-1 humana, un proceso para dicha produccion, construcciones de adn, un vector de expresion, composiciones farmaceuticas y el uso de dicha molecula de enlace de mcp-1 para la preparacion de un medicamento
AR099084A2 (es) Composiciones de anticuerpos anti-ctla-4
BR0207151A (pt) Moléculas de aglutinação terapêuticas
Pittman et al. Safety and immunogenicity of ricin vaccine, RVEc™, in a Phase 1 clinical trial
ES2066887T3 (es) Anticuerpo monoclonal para diferenciar individuos seropositivos hiv-2 de los hiv-1.
PE20230075A1 (es) Anticuerpos anti-flt3 y composiciones

Legal Events

Date Code Title Description
FC Refusal